Showcase spotlights Mursla Bio’s first-in-class science and upcoming milestones for flagship product launch
Cambridge, UK, 22nd May 2023: Mursla Bio is pleased to announce its participation in the Department for Business and Trade’s (DBT) Health Tech Showcase on 23rd May 2023 at the London Stock Exchange. This invitation-only event in the City of London features 10 leading UK health tech companies poised for growth and international expansion.
The Founder & CEO will present Mursla Bio’s first-in-class tissue-derived extracellular vesicle (tissue-EV) science and upcoming operating milestones for its flagship product launch in the US expected Q1 2025.
This event offers a great platform for domestic and international investors to engage with some of the UK’s most exciting health tech companies, hear about their transformative work and assess prospective investments.
– ENDS –
For more information contact:
Sarah Brereton, Director
Tel: +44 (0)7796 583 223
Mursla Bio, Cambridge
Pierre Arsène, Founder & CEO
Tel: +44 (0) 1223 928 141
About Mursla Bio
Mursla Bio (Cambridge, UK) is an emergent techbio company, leveraging extracellular vesicle biology to deliver nextgen liquid biopsy and precision medicine tests. Its first product is an In Vitro Diagnostics test to significantly improve the early detection of liver cancer among high-risk populations, such that more individuals can benefit from curative and lifesaving treatments. Mursla Bio’s test is first-in-class and is differentiated from first generation liquid biopsy tests using circulating free DNA as it is tissue-specific, multi-omics and offers a real time snapshot of disease biology. Mursla Bio was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.
For further information: www.mursla.com